Clinical trials have focused on the development of combined-modality treatment approaches involving novel chemotherapy agents, radiotherapy techniques and surgical approaches. These protocols represent a major collaborative effort with the departments of Thoracic/Head and Neck Medical Oncology, Gastrointestinal Oncology and Digestive Diseases and Radiation Oncology. Current protocols for lung cancer include both preoperative and postoperative adjuvant chemotherapy with novel agents. Protocols combining chemotherapy, radiotherapy and surgery are being evaluated for esophageal cancer. A novel strategy of pulmonary perfusion with doxorubicin for sarcomatous lung metastases is being evaluated. A major collaboration with the Thoracic/Head and Neck Medical Oncology department is directed toward chemoprevention of second primary cancers in patients with early-stage lung cancer. The Thoracic and Cardiovascular Surgery department has completed clinical trials to evaluate replacement of the p53 tumor suppressor gene by delivering a functional p53 tumor suppressor via retroviral and adenoviral vectors in patients with non-small cell lung cancer. New trials combining p53 gene replacement are planned in combination with radiotherapy and chemotherapy in collaboration with the Thoracic/Head and Neck Medical Oncology department.  If you are interested in participating in one of these clinical trials, please call the Information Line toll-free at 1-800-MDA-06789 or visit the MD Anderson Clinical Trials site.